Eupraxia Pharmaceuticals announces common shares offering, no amount given

Eupraxia Pharmaceuticals (EPRX) has filed a preliminary prospectus supplement to its short form base shelf prospectus dated February 5, 2024 in connection with a proposed public offering of common shares of the company. The offering is expected to be priced in the context of the market, with the final terms of the offering to be determined at the time of pricing. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The closing of the offering will be subject to customary closing conditions, including the listing of the common shares on the Toronto Stock Exchange and the Nasdaq Capital Market and any required approvals of the TSX. Cantor and LifeSci Capital are acting as joint book-running managers for the Offering. Bloom Burton is also acting as co-manager for the Offering.